To see all protocols that comply with the WHO Essential Medicine List 

Welcome to eviQ

A free resource of evidence-based, consensus driven cancer treatment protocols and information for use at the point of care. eviQ is developed for the Australian context and supports health professionals in the delivery of cancer treatments.

Find out more


Latest news

View all news

PLEASE NOTE: if your site uses the MOSAIQ system, please double check protocols containing the dose units International Units/m2 or IntU/m*2 i.e. bleomycin or asparaginase (colaspase) protocols, to verify these protocols calculate doses correctly in your electronic system.

The statement has been endorsed by the Medical Oncology Group of Australia Incorporated (MOGA), the Australasian Society for Infectious Diseases, the Gastroenterological Society of Australia, the Haematology Society of Australia and New Zealand, and the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine.

The Cancer Institute NSW Patient Information website helps people affected by cancer find trusted and reliable information relevant to their situation. The site went live with general cancer information in October 2018. Fourteen specific cancer types have now been added, with more in development.

Carboplatin has been reclassified as moderately emetogenic and antiemetics updated in the relevant protocols. Dexamethasone premedication dose has been reduced in taxane protocols with netupitant. Refer to ID 7 and attached PDF for more information.